Literature DB >> 23415456

Low 25-hydroxyvitamin D level is independently associated with non-alcoholic fatty liver disease.

K L Jablonski1, A Jovanovich, J Holmen, G Targher, K McFann, J Kendrick, M Chonchol.   

Abstract

BACKGROUND AND AIMS: We sought to explore associations between serum 25-hydroxyvitamin D [25(OH)D] levels and non-alcoholic fatty liver disease [NAFLD] in an integrated healthcare delivery system in the U.S. METHODS AND
RESULTS: Six hundred and seven NAFLD cases were randomly matched 1:1 with controls for age, sex, race and season of measurement. Conditional logistic regression was used to evaluate if serum 25(OH)D levels were associated with increased odds of NAFLD (diagnosed by ultrasound) after adjusting for body mass index and history of diabetes, renal, peripheral vascular and liver diseases (model 1) and also for hypertension (model 2). Mean (SD) serum 25(OH)D level was significantly lower in the group with NAFLD as compared with that in the matched control group (75 ± 17 vs. 85 ± 20 nmol/L [30 ± 7 vs. 34 ± 8 ng/mL], P<0.001). Inadequate 25(OH)D status progressively increased the odds of NAFLD when classified categorically as sufficient (25(OH)D 75 nmol/L [>30 ng/mL], reference group), insufficient (37-75 nmol/L [15-30 ng/mL]; adjusted odds ratio [OR]: 2.40, 95% confidence interval [CI]: 0.90-6.34) or deficient (<37 nmol/L [<15 ng/mL]; adjusted OR: 2.56, 95% CI: 1.27-5.19). When modeled as a continuous variable, increased log10 25(OH)D was inversely associated with the risk of prevalent NAFLD (adjusted OR: 0.25, 95% CI: 0.064-0.96, P=0.02).
CONCLUSION: Compared with matched controls, patients with NAFLD have significantly decreased serum 25(OH)D levels, suggesting that low 25(OH)D status might play a role in the development and progression of NAFLD.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  25(OH)D; Fatty liver; Inflammation; NAFLD; Risk factors; Vitamin D

Mesh:

Substances:

Year:  2013        PMID: 23415456      PMCID: PMC3659172          DOI: 10.1016/j.numecd.2012.12.006

Source DB:  PubMed          Journal:  Nutr Metab Cardiovasc Dis        ISSN: 0939-4753            Impact factor:   4.222


  37 in total

1.  1,25-Dihydroxyvitamin D inhibits lipopolysaccharide-induced immune activation in human endothelial cells.

Authors:  O Equils; Y Naiki; A M Shapiro; K Michelsen; D Lu; J Adams; S Jordan
Journal:  Clin Exp Immunol       Date:  2006-01       Impact factor: 4.330

2.  Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients.

Authors:  Giovanni Targher; Lorenzo Bertolini; Felice Poli; Stefano Rodella; Luca Scala; Roberto Tessari; Luciano Zenari; Giancarlo Falezza
Journal:  Diabetes       Date:  2005-12       Impact factor: 9.461

3.  In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not.

Authors:  Zobair M Younossi; Munkhzul Otgonsuren; Chapy Venkatesan; Alita Mishra
Journal:  Metabolism       Date:  2012-09-19       Impact factor: 8.694

4.  Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters.

Authors:  Patrícia João Matias; Cristina Jorge; Carina Ferreira; Marília Borges; Inês Aires; Tiago Amaral; Célia Gil; José Cortez; Aníbal Ferreira
Journal:  Clin J Am Soc Nephrol       Date:  2010-03-04       Impact factor: 8.237

5.  Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease.

Authors:  Giovanni Targher; Lorenzo Bertolini; Luca Scala; Massimo Cigolini; Luciano Zenari; Giancarlo Falezza; Guido Arcaro
Journal:  Nutr Metab Cardiovasc Dis       Date:  2006-08-22       Impact factor: 4.222

6.  Impact of cholecalciferol treatment on biomarkers of inflammation and myocardial structure in hemodialysis patients without hyperparathyroidism.

Authors:  Sérgio Bucharles; Silvio Henrique Barberato; Andréa E M Stinghen; Betina Gruber; Luciana Piekala; Ana Cláudia Dambiski; Melani R Custodio; Roberto Pecoits-Filho
Journal:  J Ren Nutr       Date:  2011-09-10       Impact factor: 3.655

7.  Liver vitamin D receptor, CYP2R1, and CYP27A1 expression: relationship with liver histology and vitamin D3 levels in patients with nonalcoholic steatohepatitis or hepatitis C virus.

Authors:  Ilaria Barchetta; Simone Carotti; Giancarlo Labbadia; Umberto Vespasiani Gentilucci; Andrea Onetti Muda; Francesco Angelico; Gianfranco Silecchia; Frida Leonetti; Antonio Fraioli; Antonio Picardi; Sergio Morini; Maria Gisella Cavallo
Journal:  Hepatology       Date:  2012-12       Impact factor: 17.425

8.  Chronic kidney disease, hypovitaminosis D, and mortality in the United States.

Authors:  Rajnish Mehrotra; Dulcie A Kermah; Isidro B Salusky; Myles S Wolf; Ravi I Thadhani; Yi-Wen Chiu; David Martins; Sharon G Adler; Keith C Norris
Journal:  Kidney Int       Date:  2009-08-05       Impact factor: 10.612

9.  Validation of a combined comorbidity index.

Authors:  M Charlson; T P Szatrowski; J Peterson; J Gold
Journal:  J Clin Epidemiol       Date:  1994-11       Impact factor: 6.437

10.  Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial.

Authors:  Pooneh Alborzi; Nina A Patel; Carla Peterson; Jennifer E Bills; Dagim M Bekele; Zerihun Bunaye; Robert P Light; Rajiv Agarwal
Journal:  Hypertension       Date:  2008-07-07       Impact factor: 10.190

View more
  27 in total

1.  Association between vitamin D and non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: results from a meta-analysis.

Authors:  Xiang Wang; Weiping Li; Ying Zhang; Yang Yang; Guijun Qin
Journal:  Int J Clin Exp Med       Date:  2015-10-15

2.  Serum 25-hydroxyvitamin-D and nonalcoholic fatty liver disease: Does race/ethnicity matter? Findings from the MESA cohort.

Authors:  Samar R El Khoudary; Saad Samargandy; Irfan Zeb; Temitope Foster; Ian H de Boer; Dong Li; Matthew J Budoff
Journal:  Nutr Metab Cardiovasc Dis       Date:  2019-09-10       Impact factor: 4.222

3.  Lower 25-hydroxyvitamin D3 levels and increased risk of liver diseases: is there a causal link?

Authors:  Giovanni Targher; Christopher D Byrne
Journal:  Endocrine       Date:  2014-03-05       Impact factor: 3.633

4.  Vitamin D is Not Associated With Severity in NAFLD: Results of a Paired Clinical and Gene Expression Profile Analysis.

Authors:  Yuval A Patel; Ricardo Henao; Cynthia A Moylan; Cynthia D Guy; Dawn L Piercy; Anna Mae Diehl; Manal F Abdelmalek
Journal:  Am J Gastroenterol       Date:  2016-09-20       Impact factor: 10.864

Review 5.  Vitamin D and chronic hepatitis C: effects on success rate and prevention of side effects associated with pegylated interferon-α and ribavirin.

Authors:  Bassem Refaat; Adel Galal El-Shemi; Ahmed Ashshi; Esam Azhar
Journal:  Int J Clin Exp Med       Date:  2015-07-15

Review 6.  Vitamin D deficiency in chronic liver disease.

Authors:  Paula Iruzubieta; Álvaro Terán; Javier Crespo; Emilio Fábrega
Journal:  World J Hepatol       Date:  2014-12-27

7.  Association and interaction between vitamin D level and metabolic syndrome for non-alcoholic fatty liver disease.

Authors:  Salam Bennouar; Abdelghani Bachir Cherif; Amel Kessira; Djamel Eddine Bennouar; Samia Abdi
Journal:  J Diabetes Metab Disord       Date:  2021-07-21

8.  Serum vitamin D is associated with non-alcoholic fatty liver disease in Chinese males with normal weight and liver enzymes.

Authors:  Ya-ping Hao; Xiao-jing Ma; Yu-qi Luo; Jie Ni; Jian-xin Dou; Ya-qin Hu; Jia-an Zhu; Yu-qian Bao; Wei-ping Jia
Journal:  Acta Pharmacol Sin       Date:  2014-08-04       Impact factor: 6.150

9.  Burden and Predictors of Non-Alcoholic Fatty Liver Disease in a Retrospective Cohort of Patients With Crohn's Disease.

Authors:  Ahmed Abomhya; Mohammed Mahmoodurrahman; Salman Ayaz; Hossam Hamad; Farrah Khan
Journal:  Gastroenterology Res       Date:  2022-04-12

10.  Lipid metabolism and inflammation modulated by Vitamin D in liver of diabetic rats.

Authors:  Conghua Ning; Lina Liu; Guodong Lv; Ye Yang; Yuanyuan Zhang; Rui Yu; Yongtao Wang; Jun Zhu
Journal:  Lipids Health Dis       Date:  2015-04-18       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.